|
Pfizer returns allergic asthma drug to Rigel
FierceBiotech Pfizer's decision to ends its allergy and respiratory R&D work has prompted the company return rights to the R343 program for allergic asthma to Rigel Pharmaceuticals. The drug has shown promise in Phase I trials and Rigel plans to begin designing a … Rigel says Pfizer returns asthma therapy rights Rigel Assumes Development Responsibility for Inhaled Asthma Therapy Pfizer Hands Back Rigel Drug |
View full post on asthma – Google News